Heart Function Checked by Ultrasound in People With Fatty Liver Disease
Uses heart ultrasound to study heart function in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Cardiac Dysfunction in Patients with Fatty Liver Disease
Key facts
- Where
- Chandigarh, IndiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-65 with metabolic dysfunction associated steatotic liver disease (fatty liver). It checks how well their heart works.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Metabolic dysfunction associated steatotic liver disease, diagnosed by biopsy or by clinical, lab, non-invasive tests, ultrasound findings and vibration controlled transient elastography (VCTE).
Main reasons for not taking part
- Age over 65
- Chronic kidney disease
- Pregnancy or peripartum cardiomyopathy
- High blood pressure (hypertension)
- Heart valve disease, heart rhythm disorder, sick sinus syndrome or pacemaker
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06386094, who can take part
Where in India
- Dr. Madhumita PremkumarChandigarh, IndiaContact: Dr. Madhumita Premkumar, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Trial code
- NCT06386094
- Record updated
- 29 January 2025
- Original description
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.Read full original descriptionShow less
Cirrhotic Cardiomyopathy and Cardiac Dysfunction in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.
Inclusion: Age range of 18-65 years; metabolic dysfunction associated steatotic liver disease as diagnosed either by histology or clinical, laboratory, non invasive tests, USG findings and vibration controlled transient elastography (VCTE).
Exclusion: Chronic renal disease; Hypertension; Valvular heart disease; Sick sinus syndrome/ Pacemaker; Cardiac rhythm disorder; Portal vein thrombosis; Age >65 years; Pregnancy and peripartum cardiomyopathy; Hypothyroidism; Hyperthyroidism; Transjugular intrahepatic porto systemic shunt (TIPS) insertion; Hepatocellular carcinoma; Anemia Hb < 8gm/dl in females, and < 9 gm/dl in males at the time of assessment.